The incidence and duration of COVID-19 vaccine-related reactive lymphadenopathy on 18F-FDG PET-CT
- PMID: 34862224
- PMCID: PMC8806286
- DOI: 10.7861/clinmed.2021-0420
The incidence and duration of COVID-19 vaccine-related reactive lymphadenopathy on 18F-FDG PET-CT
Abstract
Objectives: Reactive axillary lymph nodes (ALN) may occur post-COVID-19 vaccination. This may be confused with malignant nodal metastases on oncological imaging. We aimed to determine the reactive ALN incidence and duration on 18F-fluorodeoxyglucose positron emission tomography - computed tomography (18F-FDG PET-CT), and its relationship with gender, age and vaccine type.
Methods: A retrospective study was performed. Two-hundred and four eligible patients had 18F-FDG PET-CT between 01 January 2021 and 31 March 2021, post-vaccination with Pfizer-BioNTech or Oxford-AstraZeneca vaccine. Image analysis was performed on dedicated workstations. SPSS was used for statistical analysis.
Results: Thirty-six per cent of patients had reactive ALN until 10 weeks post-vaccination; reducing in frequency and intensity with time. Women were more likely to have reactive ALN compared with men. The frequency and intensity were higher in patients aged <65 years compared with those aged ≥65 years. However, no difference was found between both vaccine types in our study cohort.
Conclusions: Physicians' awareness of COVID-19 vaccine-related reactive ALN on 18F-FDG PET-CT is important to avoid inappropriate upstaging of cancers.
Keywords: 18F-FDG PET-CT; COVID-19 vaccine; lymphadenopathy.
© Royal College of Physicians 2021. All rights reserved.
Figures



References
-
- Baraniuk C. Covid-19: How the UK vaccine rollout delivered success, so far. BMJ 2021;372:n421. - PubMed
-
- Medicines and Healthcare products Regulatory Agency . Regulatory approval of Pfizer/BioNTech vaccine for COVID-19. REG 174 Information for UK healthcare professionals. MHRA, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploa... [Accessed 24 May 2021].
-
- Medicines and Healthcare products Regulatory Agency . Regulatory approval of COVID-19 vaccine AstraZeneca. REG 174 Information for UK healthcare professionals. MHRA, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploa... [Accessed 24 May 2021].
-
- Doss M, Nakhoda SK, Li Y, Yu JQ. COVID-19 Vaccine-Related Local FDG Uptake. Clin Nucl Med 2021;46:439–41. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical